drugset

drugset / Trial / NCT05011305

Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis

NCT05011305 ↗

Phase 2 Completed 189 enrolled Zydus Therapeutics Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis

Timeline

Start: 2021-08-18
Primary completion: 2025-09-12
Completion: 2025-09-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Saroglitazar	Small molecule	2 mg	Oral
Subject	Saroglitazar	Small molecule	4 mg	Oral

Indications